Effect of gender and age on the pharmacokinetics of repinotan

Clinical Drug Investigation

Volumn 25, Issue 2, 2005, Pages 125-134

  Heinig, Roland ^a   Sundaresan, Pavur ^b   Shali, Anita ^b   Boettcher, Michael ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; REPINOTAN; SEROTONIN 1A AGONIST;

AGE; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; ECCHYMOSIS; ELDERLY CARE; FEMALE; GENDER; HEADACHE; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; SEX DIFFERENCE; STEADY STATE; STROKE; SUPRAVENTRICULAR PREMATURE BEAT; VOMITING;

EID: 14644429011     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525020-00005     Document Type: Article

References (12)

1. 1A receptor agonist BAY x 3702 in a rat model of permanent focal cerebral ischemia and traumatic brain injury [abstract]. Soc Neurosci 1997; 23: 1923
2. 1A receptor agonist BAY x 3702 in the rat model of acute subdural hematoma [abstract]. J Neurotrauma 1997; 14: 800
3. Boettcher, M. Pupillography in clinical pharmacology. In: Kuhlmann J, Boettcher M, editors Pupillography: principles, methods and applications. Zuckschwerdt Verlag, München, 1999; 13: 13-26
4. 1A agonist in traumatically brain injured patients. J Neurotrauma 2001; 12: 1313-22
5. Teal P, on behalf of the BRAINS Study Group. BRAINS, a phase II study of the neuroprotectant, BAY x 3702 in patients with ischemic stroke [abstract]. Cerebrovasc Dis 1998; 8 Suppl. 4: 20
6. Bertilsson L, Dahl ML. Polymorphic drug oxidation. CNS Drugs 1996; 5: 200-23
7. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41: 329-42
8. Laurent-Kenesi MA, Jacqz-Aigrain E, Lejonc JL, et al. Assessment of CYP 2D6 activity in very elderly healthy subjects. Fundam Clin Pharmacol 1996; 10: 158-9
9. Pollock BG, Perel JM, Altieri LP, et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 163-8
10. Shulman R, Özdemir V. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 1997; 42 Suppl. 1: 4S-9S
11. Yamada H, Dahl ML, Lannfelt L, et al. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur J Clin Pharmacol 1998; 54: 479-81
12. Ohara K, Tanabu S, Ishibashi K, et al. Effects of age and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 945-9